Business

Announcement on Voluntary Disclosure of Obtaining Approval Notice for Phase II Drug Clinical Trials of iza-bren (EGFR×HER3 Bispecific Antibody ADC) Combination Therapy in the Treatment of Various Advanced Renal Cell Carcinoma

Announcement on Voluntary Disclosure of Obtaining Approval Notice for Phase II Drug Clinical Trials of iza-bren (EGFR×HER3 Bispecific Antibody ADC) Combination Therapy in the Treatment of Various Advanced Renal Cell Carcinoma

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AJuly 14, 20253/news/announcement-on-voluntary-disclosure-of-obtaining-approval-notice-for-phase-ii-drug-clinical-trials-of-iza-bren-egfrher3-bispecific-antibody-adc-combination-therapy-in-the-treatment-of-various-advanced-renal-cell-carcinoma
Announcement on Voluntary Disclosure of Obtaining Approval Notice for Phase II Drug Clinical Trials of iza-bren (EGFR×HER3 Bispecific Antibody ADC) Combination Therapy in the Treatment of Various Advanced Renal Cell Carcinoma

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Approval Notice for Phase II Drug Clinical Trials of iza-bren (EGFR×HER3 Bispecific Antibody ADC) Combination Therapy in the Treatment of Various Advanced Renal Cell CarcinomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A